rHEALTH Targets $323 Billion Diagnostics Market with NASA-Backed Testing Tech

rHEALTH is positioning itself to disrupt the global blood diagnostics market with a portable, lab-quality testing device designed for use in point-of-care settings and private homes. The platform aims to address a critical global health gap, as the World Health Organization estimates that 4.5 billion people currently lack timely access to diagnostic testing. Originally developed to monitor astronaut health on the International Space Station where traditional labs are unavailable, the technology has been validated in extreme conditions and is backed by the National Institutes of Health (NIH) and NASA. The system is designed to run more than 100 different tests on a single device, functioning similarly to an 'app store' for diagnostics. The company currently holds 17 U.S. patents covering its device architecture and diagnostic algorithms. To date, rHEALTH has secured more than $20 million in non-dilutive funding and established strategic partnerships with prestigious institutions, including the Mayo Clinic, Boston Children’s Hospital, Massachusetts General Hospital, and AstraZeneca. From a commercial perspective, rHEALTH is targeting a total addressable market of $323 billion, including a $16.2 billion obtainable market for hematology diagnostics. The company plans to generate revenue through a combination of device sales, recurring test cartridge purchases, and software subscriptions. FDA registration for the technology is anticipated within approximately 12 months.